Exact Sciences Stock Down on Q3 Earnings & Revenue Miss, '24 View Cut
Portfolio Pulse from
Exact Sciences (EXAS) reported a decline in stock price following a miss in Q3 earnings and revenue expectations. Despite the setback, the company saw growth in Cologuard adoption and Oncotype DX's international expansion. However, the 2024 outlook was revised downwards.
November 06, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Exact Sciences' stock fell due to a miss in Q3 earnings and revenue expectations. The company did see growth in Cologuard and Oncotype DX, but the 2024 outlook was revised downwards.
The stock price of Exact Sciences is likely to decline in the short term due to the negative impact of missing Q3 earnings and revenue expectations. Although there is growth in certain areas, the downward revision of the 2024 outlook adds to the negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100